Futur Publishes Annual and Sustainability Report for 2024
Today, Futur Pension AB (publ) publishes its Annual and Sustainability Report for 2024. Read it at www.futur.se/financial-information
We are pleased to note that Futur’s customers overall have experienced strong returns in 2024. In particular, customers with exposure to global equities, led by the U.S. market, have seen significant growth of their capital. Thereto, we are proud of high inflows of new savings and pension capital.
In line with last years, Futur has continued to invest heavily in its technology platform to ensure a high level of service and cost efficiency.
“For the coming years, we see great opportunities to continue growing by developing innovative and efficient services for savings and pension together with our partners. In 2025, we will continue our investments in digital self-service solutions to strengthen our position as the obvious choice for savings and pensions. We also look forward to more and deeper collaborations throughout the year,” says Torgny Johansson, CEO of Futur.
Key highlights 2024:
- New digital self-service interface for private customers which has contributed to reducing routine calls to customer service by more than 30%
- Awarded most innovative company and the company with the best product range in Origo’s annual survey among financial advisors in Sweden
- 4 new partners and 23,000 new customers
- 80% Y-on-Y growth in the occupational pension portfolio bond product
- Continued revenue growth (+24% Y-on-Y) and 50% higher net inflows than in 2023
Futur’s positive development continued in 2024, and the profit grew by 33% to 420 million SEK (compared to SEK 316m in 2023). This increase is explained by growing net inflows, strong returns on customers’ capital, and cost efficiency.
Key financial figures 2024 (2023):
- Revenue 998 MKR (806)
- Sales costs 459 MKR (371)
- Admin costs 119 MKR (119)
- Profit 420 MKR (316)
- Proposed dividend 350 MKR (275) corresponding to over 80% of profit
Read more in the annual report at www.futur.se/financial-information
Futur provides digital infrastructure for the savings and pension market. With our modern platform, we efficiently connect products and customers through partners who offer professional advice. Our platform enables partners to offer better savings options cost-effectively, helping more people achieve a richer and more secure future. Futur has more than 50 partners and 300,000 customers, with 235 billion SEK in savings and pension capital. For more information, visit www.futur.se
The information was submitted for publication, through the agency of the contact persons set out above, at 2025-03-17 11:00 CET.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317622387/en/
Contacts
For more information, contact:
Torgny Johansson, CEO, 08-502 225 00
Torgny.johansson@futur.se
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mark Wiseman appointed Chairman of Alter Domus18.3.2025 07:00:00 EET | Press release
Alter Domus, the leading global provider of tech-enabled fund services for the private equity, real assets and private debt sectors today appointed Mark Wiseman as Chairman. Mr. Wiseman is the former Head of Active Equities and Chairman of BlackRock’s Alternatives Business, as well as President & CEO of Canada Pension Plan Investment Board (CPPIB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317232851/en/ Mark Wiseman Following a successful tenure, René Beltjens will step down as Chairman but will retain his seat on the Board. As alternatives specialists, with $3 trillion assets under administration (AUA), Alter Domus’ end-to-end servicing expertise enables asset managers to focus on investing and creating outsized returns for investors. Alter Domus’ leadership in alternatives and market share growth has been achieved by significant investments in fund administration services and debt capital market solutions. As a tec
Brisbane Airport embraces advanced analytics from Cirium Sky Warehouse18.3.2025 00:00:00 EET | Press release
Brisbane Airport (BNE), which serves as the major gateway to Queensland, has partnered with aviation analytics firm, Cirium, to become one of the first airports to integrate Cirium Sky Warehouse, a data-driven cloud platform, into its modernisation efforts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317052819/en/ Brisbane Airport Cirium’s advanced data and analytics will be seamlessly integrated with Brisbane Airport’s business systems. This integration will support enhanced capacity planning, resource allocation, and operations analysis. Jeremy Bowen, Cirium CEO, commented: "We are delighted to support Brisbane Airport’s transformative investment to revolutionise its passenger experience and meet future travel demand. “Integrating Cirium data and analytics through the Cirium Sky Warehouse will help the airport to consolidate and accelerate digitization, leading to improved decision-making and operational performance.
Trump-Inspired World Liberty Financial Closes $550 Million Across Token Sales17.3.2025 21:37:00 EET | Press release
World Liberty Financial, Inc. (“WLFI”), the developer of a pioneering DeFi protocol and governance platform inspired by Donald J. Trump, has made history with the completion of the second set of its token sales, totaling $550 million in gross proceeds in concurrent U.S. and non-U.S. token offerings. After launching on October 15, 2024, WLFI has successfully concluded two sets of token sales in concurrent U.S. and non-U.S. offerings. In the first set, $300 million USD of WLFI tokens were sold between the offerings, and in the second set, $250 million USD of WLFI tokens were sold between the offerings. Between all the offerings, $550 million USD in WLFI tokens have been sold. More than 85,000 total participants in the token sales underwent Know Your Customer (KYC) process to determine participation eligibility. "This milestone proves that those who truly understand crypto and finance recognize what we’re building — and that WLFI is on track to supercharge DeFi as it transforms global fin
RevBio Initiates its Pivotal Clinical Trial in Europe for its Dental Implant Stabilization Product17.3.2025 21:28:00 EET | Press release
RevBio, Inc., announced that it has received regulatory and ethics committee approvals in multiple European countries to conduct its pivotal clinical trial for its dental implant stabilization product. The successful completion of this pivotal clinical trial will result in the CE marking approval for the product, which will allow the company to begin commercial sales in Europe. As of the date of this press release, the company has already enrolled 30 of an expected 75 patients in this clinical trial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250306978603/en/ RevBio initiates a pivotal clinical trial in Europe for its Dental Implant Stabilization product with 30 of 75 expected patient enrollments. Clinical Images courtesy of Prof. France Lambert of the University of Liege. “The results from this ongoing international multicenter study are exceeding expectations, showcasing remarkable outcomes. We are profoundly optimisti
Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 203017.3.2025 20:00:00 EET | Press release
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance. Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases. Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response. In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom